September 15, 2021•Publication
Gates MRI’s Chief Medical Officer and Head of Development, Michael Dunne; Program Lead Mohamed Bassyouni; Head of Global Regulatory Strategy & Operations, Taryn Rogalski-Salter; Head of Translational Discovery, Jared Silverman; and Program Leads Jeroen Medema and Mohamed Bassiouni investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 2019 (COVID-19) progression.
September 7, 2021•Publication
Gates MRI’s Research Project Manager, Judith Maxwell Silverman, contributed to research demonstrating how a bioengineered yeast production strain combined with an optimized version of the SARS-CoV-2 spike protein receptor-binding domain (RBD) exhibits improved biomolecular attributes that are well-suited for further development for large-volume manufacturing of low-cost vaccine candidate.